Alane P Barnes sold $1.4M of BCRX
Chief Legal Officer at BIOCRYST PHARMACEUTICALS INC. 150,000 shares at an average of $9.15, traded Mar 16, 2026, filed Mar 18, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.4M at market
- +10Share of holdings soldSold 27% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.7%, 3m -2.3%, 6m -8.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000882796-26-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | MOption exercise Common Stock10b5-1 | +150,000 | $5.51 | $827k | 550,703 | Mar 18, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -150,000 | $9.15 | $1.4M | 400,703 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Emp. Stock Option (Right to Buy)derivative10b5-1 | -150,000 | $0.00 | $0 | 0 | Mar 18, 2026 |
Related signals
Other insiders at BIOCRYST PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | BIOCRYST PHARMACEUTICALS INC | Amy E McKee director | $100k 11,180 shares | -26% | |
| 12Weak | BIOCRYST PHARMACEUTICALS INC | Alane P Barnes Chief Legal Officer | $596k 62,500 shares | -13% | |
| 36Weak | BIOCRYST PHARMACEUTICALS INC | Theresa Heggie director | $505k 49,933 shares | -43% | |
| 6Weak | BIOCRYST PHARMACEUTICALS INC | Alane P Barnes Chief Legal Officer | $167k 21,773 shares | -5% | |
| 6Weak | BIOCRYST PHARMACEUTICALS INC | Alane P Barnes Chief Legal Officer | $162k 21,210 shares | -6% | |
| 15Weak | BIOCRYST PHARMACEUTICALS INC | Alane P Barnes Chief Legal Officer | $1.2M 161,680 shares | -32% | |
| 8Weak | BIOCRYST PHARMACEUTICALS INC | Machelle Sanders director | $69k 9,600 shares | -24% | |
| 39Weak | BCRXsell BIOCRYST PHARMACEUTICALS INC | Theresa Heggie director | $596k 70,000 shares | -52% | |
| 2Weak | BIOCRYST PHARMACEUTICALS INC | Nancy J Hutson director | $53k 7,000 shares | -7% | |
| 42Moderate | BIOCRYST PHARMACEUTICALS INC | Amy E McKee director | $54k 8,600 shares | -24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.